目的 探讨灯盏生脉胶囊联合注射用重组人脑利钠肽治疗慢性心力衰竭的临床疗效。方法 选取2016年2月-2018年2月恩施自治州中心医院治疗的84例慢性心力衰竭患者为研究对象，采用随机数字表将患者分为对照组（42例）和治疗组（42例）。对照组给予注射用重组人脑利钠肽，首次静脉冲击1.5 μg/kg，随后按照0.01 μg/（kg·min）静脉泵入。治疗组在对照组治疗的基础上口服灯盏生脉胶囊，2粒/次，3次/d。两组患者均连续治疗2周。观察两组临床疗效，比较治疗前后两组患者的心功能指标和血清学指标。结果 治疗后，对照组和治疗组的总有效率分别为80.95%、97.62%，两组比较差异具有统计学意义（P<0.05）。治疗后，两组左室射血分数（LVEF）显著升高，左心室舒张末期内径（LVEDD）、左心室收缩末期内径（LVESD）、左心室收缩末期容积（LVESV）均显著降低，同组治疗前后比较差异具有统计学意义（P<0.05）。治疗后，治疗组心功能指标显著优于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组血清可溶性糖化终末产物受体（sRAGE）、高迁移率族蛋白1（HMGB1）、N-末端B型脑钠肽前体（NT-proBNP）、转化生子因子-β1（TGF-β1）、β-内啡肽（β-EP）水平均降低，同组治疗前后比较差异具有统计学意义（P<0.05）。治疗后，治疗组血清学指标水平显著低于对照组，两组比较差异具有统计学意义（P<0.05）。结论 灯盏生脉胶囊联合注射用重组人脑利钠肽治疗慢性心力衰竭具有较好的临床疗效，可有效改善患者心功能，降低血清学指标水平，具有一定的临床推广应用价值。

Objective To investigate the clinical effects of Dengzhan Shengmai Capsules combined with Recombinant Human Brain Natriuretic Peptide for injection in treatment of chronic heart failure. Methods Patients (84 cases) with chronic heart failure in the Central Hospital of Enshi Autonomous Prefecture from February 2016 to February 2018 were randomly divided into control (42 cases) and treatment (42 cases) groups. Patients in the control group were iv administered with Recombinant Human Brain Natriuretic Peptide for injection, and the first dosage of intravenous pulse was 1.5 μg/kg, followed by 0.01 μg/(kg·min). Patients in the treatment group were po administered with Dengzhan Shengmai Capsules on the basis of the control group, 2 grains/time, three times daily. Patients in two groups were treated for 2 weeks. After treatment, the clinical efficacies were evaluated, and the cardiac function indexes and the serological indexes in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 80.95% and 97.62%, respectively, and there were differences between two groups (P<0.05). After treatment, LVEF in two groups were significantly increased, but LVEDD, LVESD, and LVESV in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). After treatment, the cardiac function indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of sRAGE, HMGB1, NT-proBNP, TGF-β1, and β-EP in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). After treatment, the serological indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Dengzhan Shengmai Capsules combined with Recombinant Human Brain Natriuretic Peptide for injection has clinical curative effect in treatment of chronic heart failure, can effectively improve the cardiac function and reduce the level of serological indexes, which has a certain clinical application value.